Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-A02663-54 | Registry Identifier | IDRCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study aims to study transition toward schizophrenia in patients with learning disorders, and to compare the risk between patients with specific learning disorders, and patients with complexed learning disorders (by two types: patients with other neuro-developmental disorders including executive function disorders, and patients with anxiety).
As secondary objectives, the study aims to:
This study will be conducted in Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP, in France.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comparator group | Specific learning disorders group |
| |
| neuro-developmental complexed group | Group of neuro-developmental complexe of learning |
| |
| Complexed with anxiety | Disorders in learning with anxiety |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standardised semi-structured talk | Diagnostic Test | Comprehensive assessment of at-risk mental states (CAARMS) will be used. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Semi-structured interview | Assessement with Comprehensive Assessment of At-Risk Mental States (CAARMS) during 6 to 90 minutes at the center of Raymond Poincaré hospital. The unique collection during the interview, quotation of each patient will be given from the assessement. There will be 4 groups by the results: CAARMS negative subjects, vulnerable subjects, attenuated psychosis subjects and subjects with brief and limited intermittent psychotic syndrome. The further statistic comparison will be done between the 3 last groups classified with results of CAARMS. | At baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Autistic screening | Autism-spectrum quotient (AQ) auto-questionnaire will be used to evaluate difficulty in social interaction. | At baseline |
| Anxiety measuring | An inventory for measuring clinical anxiety: Beck Anxiety Inventory |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients between 15 and 30 years, suffering learning disorders complicated with two orders: with other neuro-developmental, or with anxiety (vs specific: comparator group).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emilie SCHLUMBERGER, MD | Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP | Principal Investigator |
| Albane Mansoux | Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré | Garches | 92380 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D007859 | Learning Disabilities |
| D011618 | Psychotic Disorders |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D003147 | Communication Disorders |
| D019954 | Neurobehavioral Manifestations |
Not provided
Not provided
Not provided
Not provided
Not provided
| Autistic spectre disorder screening | Diagnostic Test | Autism-spectrum quotient (AQ) auto-questionnaire will be used. |
|
| Anxiety measuring | Diagnostic Test | An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale. |
|
| At baseline |
| Social interaction difficulty evaluation | Liebowitz Social Anxiety Scale as questionnaire | At baseline |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |